AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of a supplemental new drug application that updates the indication statement for RINVOQ for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn’s disease. Previously, RINVOQ was indicated for adults with moderately to severely active UC or CD who had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The updated indication statement also allows the use of RINVOQ for patients after they have received at least one approved systemic therapy in the event TNF blockers are clinically inadvisable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie to present new data from ADC platform at ESMO
- AbbVie price target raised to $284 from $231 at Piper Sandler
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- AbbVie price target raised to $250 from $245 at Cantor Fitzgerald
- Aldeyra price target raised to $7 from $6 at Jefferies